Safety and Efficacy Data From Company's Human Neural Stem Cells Featured in Neuroscience 2014 Press Program "Advances Through Stem Cell Research" CARLSBAD, CA-- - International Stem Cell Corporation , a California-based biotechnology company developing novel stem cell based therapies and biomedical products, announced today preclinical data from its Parkinson's disease program. ISCO's Chief Scientific Officer Ruslan Semechkin, Ph.D., will discuss the data at the "Advances Through Stem Cell Research" press conference at the Society for Neuroscience's annual meeting at 10 a.m. on Nov. 18 in Washington, D.C. The preclinical data will form the basis for the Company's regulatory submission for its Phase 1 study in Parkinson's disease.
http://ift.tt/1u7lFSd
http://ift.tt/1u7lFSd
No comments:
Post a Comment